• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

Encorafenib

CAS No. 1269440-17-6

Encorafenib ( LGX818 | LGX-818 | LGX 818 | Encorafenib )

产品货号. M17919 CAS No. 1269440-17-6

LGX818是一种口服的突变BRaf V600E抑制剂(IC50=0.3 nM),具有潜在的抗肿瘤活性。

纯度: >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
5MG ¥697 有现货
10MG ¥1004 有现货
25MG ¥1596 有现货
50MG ¥3029 有现货
100MG 获取报价 有现货
200MG 获取报价 有现货
500MG 获取报价 有现货
1G 获取报价 有现货

生物学信息

  • 产品名称
    Encorafenib
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    LGX818是一种口服的突变BRaf V600E抑制剂(IC50=0.3 nM),具有潜在的抗肿瘤活性。
  • 产品描述
    Encorafenib, also known as LGX-818, is an orally available Raf kinase inhibitor with potential antineoplastic activity. LGX818 specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway. By inhibiting the activation of the RAF/MEK/ERK signaling pathway, the administration of LGX818 may result in a decrease in proliferation of tumor cells.(In Vitro):Encorafenib (LGX818) is a potent drug that can prevents diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf. Encorafenib (LGX818) (10 nM) suppresses the ERK/MAPK pathway and displays marked inhibition of pERK in A375, G361 and SK-MEL-24 cells. 10 nM Encorafenib (LGX818) treatment for 12 days potently inhibits colony formation in A375, G361 and SK-MEL-24 cells, but not in RPMI7951 and C8161 cells. Encorafenib (LGX818) treatment induces a steady increase in the β-catenin level in G361 cells over time.
  • 体外实验
    Encorafenib (LGX818) is a potent drug that can prevents diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf. Encorafenib (LGX818) (10 nM) suppresses the ERK/MAPK pathway and displays marked inhibition of pERK in A375, G361 and SK-MEL-24 cells. 10 nM Encorafenib (LGX818) treatment for 12 days potently inhibits colony formation in A375, G361 and SK-MEL-24 cells, but not in RPMI7951 and C8161 cells. Encorafenib (LGX818) treatment induces a steady increase in the β-catenin level in G361 cells over time.
  • 体内实验
    ——
  • 同义词
    LGX818 | LGX-818 | LGX 818 | Encorafenib
  • 通路
    Cell Cycle/DNA Damage
  • 靶点
    HDAC
  • 受体
    B-Raf (V600E)
  • 研究领域
    Cancer
  • 适应症
    ——

化学信息

  • CAS Number
    1269440-17-6
  • 分子量
    540.01
  • 分子式
    C22H27ClFN7O4S
  • 纯度
    >98% (HPLC)
  • 溶解度
    DMSO : 50 mg/mL 92.59 mM;
  • SMILES
    C[C@@H](CNC1=NC=CC(=N1)C2=CN(N=C2C3=CC(=CC(=C3F)NS(=O)(=O)C)Cl)C(C)C)NC(=O)OC
  • 化学全称
    (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate.

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

1. Darrin D Stuart, et al. Cancer Res, 2012, 72(8 Supplement): 3790.
产品手册
关联产品
  • PCI-24781

    广谱 HDAC 抑制剂;抑制纯重组 HDAC1,Ki 为 7 nM。

  • CHDI-390576

    CHDI-390576 (CHDI390576) 是一种有效的、细胞渗透性和 CNS 渗透性 IIa 类 HDAC 抑制剂。

  • YPX-C-05

    YPX-C-05 是一种基于异羟肟酸的 HDAC 抑制剂。YPX-C-05 具有显着的血管舒张作用。YPX-C-05 对 HDAC 表现出抑制作用,并增加内皮细胞中的组蛋白 H4 乙酰化。YPX-C-05 可用于高血压研究。